Oncotarget

Reviews:

Driving better and safer HER2-specific CARs for cancer therapy

Xianqiang Liu, Nan Zhang and Huan Shi _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:62730-62741. https://doi.org/10.18632/oncotarget.17528

Metrics: PDF 1452 views  |   HTML 3375 views  |   ?  


Abstract

Xianqiang Liu1,*, Nan Zhang2,* and Huan Shi3

1Department of Breast and Thyroid Surgery, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China

2Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China

3Department of Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong, P.R. China

*These authors contributed equally to this work

Correspondence to:

Huan Shi, email: huanshidoc@gmail.com

Keywords: chimeric antigen receptor, HER2, cancer, immunotherapy, toxicity

Received: March 20, 2017     Accepted: April 14, 2017     Published: April 29, 2017

ABSTRACT

Given the clinical efficacy of chimeric antigen receptor (CAR)-based therapy in hematological malignancies, CAR T-cell therapy for a number of solid tumors has been actively investigated. Human epidermal growth factor receptor 2 (HER2) is a well-established therapeutic target in breast, as well as other types of cancer. However, HER2 CAR T cells pose a risk of lethal toxicity including cytokine release syndrome from “on-target, off-tumor” recognition of HER2. In this review, we summarize the development of conventional HER2 CAR technology, the alternative selection of CAR hosts, the novel HER2 CAR designs, clinical studies and toxicity. Furthermore, we also discuss the main strategies for improving the safety of HER2 CAR-based cancer therapies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17528